When people find out that I once worked in a Wall Street firm they often ask me what stocks they should be buying. They also ask which Alzheimer's stock they should buy......I am not in the habit of recommending stocks. Its not my job. So I'll start by saying this is not a recommendation. On the other hand, the site statistics indicate that a large fraction of the readers that come to this website are interested in investing.
I wanted to bring this into you awareness, but it is up to you to decided which investments are appropriate for you.
Full disclosure: I am in the process of determining if my mother is a candidate for the Dimebon with Namenda clinical trial. Protocol Number: B1451006
No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe Alzheimer's disease who are receiving existing background therapy with memantine (namenda).
MDVN Starts New Alzheimer’s Trials
Earlier this month, Medivation, Inc. (MDVN - Analyst Report) and Pfizer, Inc. (PFE - Analyst Report) initiated two phase III studies, CONTACT and CONSTELLATION, with Dimebon in patients with moderate-to-severe Alzheimer's disease (AD). Dimebon is being developed in collaboration with Pfizer for the treatment of Alzheimer’s and Huntington diseases.
The CONTACT study will assess the potential benefits of adding Dimebon to ongoing treatment with Pfizer’s Aricept on neuropsychiatric symptoms and activities of daily living. Meanwhile, the CONSTELLATION study will evaluate the effects of adding Dimebon to Forest Lab’s (FRX - Analyst Report) Namenda, another standard of care, on cognition, memory and activities of daily living.
Preclinical studies indicate that Dimebon has the potential to protect brain cells from damage and enhance brain cell survival, by stabilizing and improving mitochondrial function. Dimebon’s mechanism is distinct from currently available Alzheimer’s medications.
Dimebon is currently in seven studies which are evaluating the safety and efficacy of the candidate across all stages of Alzheimer's disease, both as monotherapy as well as in combination with currently available Alzheimer's treatments, and in Huntington disease.
Dimebon’s unique mechanism of action and efficacy seen in clinical trials could make it a significant player in the worldwide Alzheimer’s market, which represents huge commercial potential. It is estimated that the market is currently worth about $5 billion.
Dimebon has successfully completed the first of two pivotal trials required to gain marketing approval in the U.S. for mild-to-moderate Alzheimer’s disease. A second confirmatory phase III study, CONNECTION, is currently ongoing. We expect to see top-line results from this study in the first half of 2010. Positive results should allow Medivation to go ahead with the filing of the new drug application (NDA) for the Alzheimer’s indication in 2011.
We currently have a Neutral recommendation on Medivation.
All of the above investment information is from Zacks investment research. It does not represent any opinion on our part.
To read more about Medivation and Dimebon -- go here.
Popular articles on the Alzheimer's Reading Room
Bob DeMarco is the editor of the Alzheimer's Reading Room and an Alzheimer's caregiver. The Alzheimer's Reading Room is the number one website on the Internet for news, advice, and insight into Alzheimer's disease. Bob has written more than 950 articles with more than 8,000 links on the Internet. Bob resides in Delray Beach, FL.
Original content Bob DeMarco, Alzheimer's Reading Room